Cargando…

Evaluation of Technology-Enabled Monitoring of Patient-Reported Outcomes to Detect and Treat Toxic Effects Linked to Immune Checkpoint Inhibitors

IMPORTANCE: Immune checkpoint inhibitors can produce distinct toxic effects that require prompt recognition and timely management. OBJECTIVE: To develop a technology-enabled, dynamically adaptive protocol that can provide the accurate information needed to inform specific remedies for immune toxic e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Msaouel, Pavlos, Oromendia, Clara, Siefker-Radtke, Arlene O., Tannir, Nizar M., Subudhi, Sumit K., Gao, Jianjun, Wang, Yinghong, Siddiqui, Bilal A., Shah, Amishi Y., Aparicio, Ana M., Campbell, Matthew T., Zurita, Amado J., Shaw, Leah K., Lopez, Lidia P., McCord, Heather, Chakraborty, Sandip N., Perales, Jacqueline, Lu, Cong, Van Alstine, Michael L., Elashoff, Michael, Logothetis, Christopher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2021
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406081/ https://www.ncbi.nlm.nih.gov/pubmed/34459906 http://dx.doi.org/10.1001/jamanetworkopen.2021.22998

Ejemplares similares

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events
por: Siddiqui, Bilal A, et al.
Publicado: (2021)

Plasma cytokine and angiogenic factors associated with prognosis and therapeutic response to sunitinib vs everolimus in advanced non-clear cell renal cell carcinoma
por: Msaouel, Pavlos, et al.
Publicado: (2017)

Molecular hallmarks of renal medullary carcinoma: more to c-MYC than meets the eye
por: Msaouel, Pavlos, et al.
Publicado: (2020)

Combination antiangiogenic tyrosine kinase inhibition and anti‐PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes
por: Laccetti, Andrew L., et al.
Publicado: (2021)

Erdafitinib for locally advanced or metastatic urothelial carcinoma
por: Siefker-Radtke, Arlene O, et al.
Publicado: (2022)

Long-Term Survival Outcomes of Cytoreductive Nephrectomy Combined with Targeted Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Individual Patient Data Meta-Analysis
por: Esagian, Stepan M., et al.
Publicado: (2021)

Association of High-Intensity Exercise with Renal Medullary Carcinoma in Individuals with Sickle Cell Trait: Clinical Observations and Experimental Animal Studies
por: Shapiro, Daniel D., et al.
Publicado: (2021)

A Phase II Clinical Trial of Pembrolizumab Efficacy and Safety in Advanced Renal Medullary Carcinoma
por: Nze, Chijioke, et al.
Publicado: (2023)

Multimodal kidney‐preserving approach in localised and locally advanced high‐risk upper tract urothelial carcinoma
por: Alhalabi, Omar, et al.
Publicado: (2021)

Real-World Experience With Cabozantinib in Metastatic Clear Cell Renal Cell Carcinoma: A Retrospective Analysis
por: Lemke, Emily A., et al.
Publicado: (2019)

Efficacy and Safety of Bevacizumab Plus Erlotinib in Patients with Renal Medullary Carcinoma
por: Wiele, Andrew J., et al.
Publicado: (2021)

Immune correlates in a Phase II clinical trial with ipilimumab in combination with finite androgen deprivation therapy in patients with metastatic non-castrate prostate cancer
por: Subudhi, Sumit K, et al.
Publicado: (2015)

Review of Immune-Related Adverse Events in Prostate Cancer Patients Treated with Ipilimumab: MD Anderson Experience
por: Gao, Jianjun, et al.
Publicado: (2015)

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma
por: Karam, Jose A., et al.
Publicado: (2023)

Acute rhabdomyolysis with severe polymyositis following ipilimumab-nivolumab treatment in a cancer patient with elevated anti-striated muscle antibody
por: Bilen, Mehmet Asim, et al.
Publicado: (2016)

Clinical and Pathological Complete Remission in a Patient With Metastatic Renal Cell Carcinoma (mRCC) Treated With Sunitinib: Is mRCC Curable With Targeted Therapy?
por: Shah, Amishi Y., et al.
Publicado: (2015)

Anti-PD-L1 plus enzalutamide does not improve overall survival in prostate cancer
por: Siddiqui, Bilal A., et al.
Publicado: (2022)

Diagnostic value of circulating tumor cell detection in bladder and urothelial cancer: systematic review and meta-analysis
por: Msaouel, Pavlos, et al.
Publicado: (2011)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
por: Viscuse, Paul V., et al.
Publicado: (2021)

Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
por: Subudhi, Sumit K, et al.
Publicado: (2021)

Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
por: Tannir, Nizar M, et al.
Publicado: (2022)

The role of the insulin-like growth factor-1 system in breast cancer
por: Christopoulos, Panagiotis F, et al.
Publicado: (2015)

Inhibition of Inducible Heat Shock Protein-70 (Hsp72) Enhances Bortezomib-Induced Cell Death in Human Bladder Cancer Cells
por: Qi, Wei, et al.
Publicado: (2013)

Specific micro-RNA expression patterns distinguish the basal and luminal subtypes of muscle-invasive bladder cancer
por: Ochoa, Andrea E., et al.
Publicado: (2016)

Cardiometabolic healthcare for men with prostate cancer: an MD Anderson Cancer Center experience
por: Hahn, Andrew W., et al.
Publicado: (2023)

Spermatozoal sensitive biomarkers to defective protaminosis and fragmented DNA
por: Angelopoulou, Roxani, et al.
Publicado: (2007)

Targeting proteostasis and autophagy in SMARCB1-deficient malignancies: where next?
por: Msaouel, Pavlos, et al.
Publicado: (2019)

Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials
por: Hahn, Andrew W, et al.
Publicado: (2020)

Application of a Successful Germ Cell Tumor Paradigm to the Challenges of Common Adult Solid Cancers
por: Tu, Shi-Ming, et al.
Publicado: (2021)

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies
por: Alhalabi, Omar, et al.
Publicado: (2023)

Overwintering and breeding patterns of monarch butterflies (Danaus plexippus) in coastal plain habitats of the southeastern USA
por: Kendrick, Michael R., et al.
Publicado: (2023)

Vicarious Hæmoptysis
por: McCord, J. S.
Publicado: (1876)

A Phase II, single-arm study of nivolumab in patients with metastatic or unresectable urothelial cancer who have progressed following treatment with a platinum agent
por: Sharma, Padmanee, et al.
Publicado: (2015)

Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical Outcomes
por: Msaouel, Pavlos, et al.
Publicado: (2021)

Missing the trees for the forest: most subgroup analyses using forest plots at the ASCO annual meeting are inconclusive
por: Hahn, Andrew W., et al.
Publicado: (2022)

Interpreting Randomized Controlled Trials
por: Msaouel, Pavlos, et al.
Publicado: (2023)

Borland C++ 3.1 programmer's reference
por: McCord, James W.
Publicado: (1992)

Library effectiveness: a systems approach
por: Morse, Philip McCord
Publicado: (1968)

MMPI-2-RF : una guía para la interpretación /
por: McCord, David M.
Publicado: (2019)

Thermal physics
por: Morse, Philip McCord
Publicado: (1969)

Cannot write session to /tmp/vufind_sessions/sess_rjj465cersmuq4mbkt4hdrvhkh